...
首页> 外文期刊>BMC Pulmonary Medicine >Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma
【24h】

Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma

机译:支气管热成形术后神经消融和重度哮喘持续改善

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Bronchial thermoplasty (BT) is a non-pharmacological intervention for severe asthma whose mechanism of action is not completely explained by a reduction of airway smooth muscle (ASM). In this study we analyzed the effect of BT on nerve fibers and inflammatory components in the bronchial mucosa at 1?year. Endobronchial biopsies were obtained from 12 subjects (mean age 47?±?11.3?years, 50% male) with severe asthma. Biopsies were performed at baseline (T0) and after 1 (T1), 2 (T2) and 12 (T12) months post-BT, and studied with immunocytochemistry and microscopy methods. Clinical data including Asthma Quality of Life Questionnaire (AQLQ) and Asthma Control Questionnaire (ACQ) scores, exacerbations, hospitalizations, oral corticosteroids use were also collected at the same time points. A statistically significant reduction at T1, T2 and T12 of nerve fibers was observed in the submucosa and in ASM compared to T0. Among inflammatory cells, only CD68 showed significant changes at all time points. Improvement of all clinical outcomes was documented and persisted at the end of follow up. A reduction of nerve fibers in epithelium and in ASM occurs earlier and persists at one year after BT. We propose that nerve ablation may contribute to mediate the beneficial effects of BT in severe asthma. Registered on April 2, 2013 at ClinicalTrials.gov Identifier: NCT01839591 .
机译:支气管热成形术(BT)是针对重度哮喘的非药物干预措施,其作用机理尚未完全由气道平滑肌(ASM)减少来解释。在这项研究中,我们分析了BT对1年时支气管黏膜神经纤维和炎性成分的影响。支气管内活检取自12名重度哮喘患者(平均年龄47±11.3岁,男性50%)。在BT后的基线(T0)和1(T1),2(T2)和12(T12)月后进行活检,并用免疫细胞化学和显微镜方法进行研究。还同时收集了包括哮喘生活质量问卷(AQLQ)和哮喘控制问卷(ACQ)评分,病情加重,住院,口服糖皮质激素的使用在内的临床数据。与T0相比,在粘膜下层和ASM中观察到神经纤维在T1,T2和T12处的统计学显着降低。在炎性细胞中,只有CD68在所有时间点都显示出明显的变化。记录所有临床结局的改善,并在随访结束时持续存在。上皮和ASM中神经纤维的减少较早发生,并持续到BT后一年。我们建议神经消融可能有助于介导BT对严重哮喘的有益作用。于2013年4月2日在ClinicalTrials.gov上注册标识符:NCT01839591。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号